The ACR has published an update to its guideline on gout management, which was mostly based on the results of randomized controlled trials (RCTs). Although rigorous, the methodology used for these recommendations can be called into questioned given the lack of robust data from RCTs on all aspects of gout.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kuo, C. F. et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 11, 649–662 (2015).
Richette, P. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 76, 29–42 (2017).
Pascart, T. et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: urate-lowering therapy. Joint Bone Spine https://doi.org/10.1016/j.jbspin.2020.05.002 (2020).
FitzGerald, J. D. et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 72, 879–895 (2020).
Sheridan, D. J. & Julian, D. G. Achievements and limitations of evidence-based medicine. J. Am. Col. Cardiol. 68, 204–213 (2016).
Dalbeth, N. et al. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal- Associated Disease Network (G-CAN). Nat. Rev. Rheumatol. 13, 561–568 (2017).
Richette, P. et al. Response: Renal dosing of allopurinol results in suboptimal gout care by T. Neogi et al. Ann. Rheum. Dis. 76, e2 (2017).
White, W. B. et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N. Engl. J. Med. 378, 1200–1210 (2018).
Ghang, B. et al. Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial. Rheumatology 59, 1439–1440 (2020).
MacDonald, T. M. et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open 4, e005354 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.B. declares that he has received advisory fees from AstraZeneca, Grunenthal and Novartis, and educational presentation fees from Astellas, Grunenthal and Novartis. P.R. declares that he has received fees from AstraZeneca, Ipsen Pharma/Menarini and Savient.
Rights and permissions
About this article
Cite this article
Bardin, T., Richette, P. Can gout management guidelines be solely evidence based?. Nat Rev Rheumatol 16, 479–480 (2020). https://doi.org/10.1038/s41584-020-0471-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0471-8
